Wednesday, October 30, 2013

Accera Announces Results of Study Effects of Axona in Patients With Mild-to-Moderate Alzheimer's Disease

Accera, Inc., a privately-held, commercial-stage, healthcare company focused on the discovery and development of innovative clinical applications to address acute and chronic neurodegenerative diseases, announced today the publication of results in the peer-reviewed open access journal Neuropsychiatric Disease and Treatment.

The study involved a retrospective review of medical records for patients taking Axona®, a prescription non-drug therapy that addresses a crucial aspect of Alzheimer's disease (AD) known as diminished cerebral glucose metabolism (DCGM). DCGM is characterized by the brain's inability to effectively metabolize glucose, its primary energy source.

Continue Reading

To learn more about Alzheimer's and Dementia care visit the Alzheimer's Reading Room